<unk>  is treated with anti-inflammatory medications. Steroids such as prednisone are used to treat severe symptoms of<unk> 's. Other commonly used medications include hydroxychloroquine, penicillamine, azathioprine, methotrexate, etanercept, anakinra, tocilizumab, cyclophosphamide, adalimumab, rituximab, and infliximab. Newer medications target interleukin-1 (IL-1), particularly IL-1β. A randomized, multicenter trial reported better outcomes in a group of 12 patients treated with anakinra than in a group of 10 patients taking other<unk> -modifying antirheumatic drugs. On June 2020 FDA approved Ilaris (canakinumab) for the treatment of<unk> , this is the first FDA approved treatment for<unk> . Canakinumab is another anti-IL1 drug which selectively binds IL-1β and rilonacept which blocks both IL-1A and IL-1β. The monoclonal anti-IL6 antibody tocilizumab is another treatment option as effective as anakinra. The condition "juvenile-onset<unk> 's<unk> " is now usually grouped under juvenile rheumatoid arthritis. However, there are obvious similarities between the two conditions, and there is some evidence that they may be closely related.
Adult-onset Still's disease
Boutonneuse fever
Far East scarlet-like fever
Barcoo fever
Tomato fever
Haverhill fever
Murine typhus
Quartan fever